Mihir Patel

Beyond Conventional Adcs: Engineering The Next Generation of Antibody–Drug Conjugates For Cancer Therapy

Antibody–drug conjugates (ADCs) are often optimized one component at a time even though clinical performance emerges from interactions among target density, internalisation, linker stability, payload mechanism, drug-to-antibody ratio (DAR), tumour penetration and resistance. This paper introduces the Multi-Parameter Ad...